NCT05172037View on ClinicalTrials.gov

Novaferon in Non-hospitalized Adult Patients With Mild COVID-19

PHASE3UnknownINTERVENTIONAL
Enrollment

222

Participants

Timeline

Start Date

October 28, 2021

Primary Completion Date

March 31, 2022

Study Completion Date

June 30, 2022

Conditions
Covid19
Interventions
BIOLOGICAL

Novaferon

a novel recombinant antiviral protein drug

BIOLOGICAL

Placebo

Saline

Trial Locations (1)

Unknown

RECRUITING

Tokyo Shinagawa Hospital, Tokyo

Sponsors

Lead Sponsor

Genova Inc.
All Listed Sponsors
collaborator

Tokyo Shinagawa Hospital

OTHER

lead

Genova Inc.

INDUSTRY

NCT05172037 - Novaferon in Non-hospitalized Adult Patients With Mild COVID-19 | Biotech Hunter | Biotech Hunter